Blindness, Liver Fibrosis, & Cancer

October 2018

1

Lin Bioscience is a drug development company focused on sourcing/advancing first-in-

class therapeutic candidates in areas with significant unmet need, and then out-license

these assets for partnership.

The Company’s pipeline consists 2 technology platforms (RBP4 platform & CDC7

platform) and 4 distinct small molecule drug candidates:

• 008: Dry Age-Related Macular Degeneration & Stargardt Disease

• 009: Non-Alcoholic Fatty Liver Disease & Type 2 Diabetes

• 007: Acute leukemia & Solid tumors

• 002: Glioblastoma & Brain metastasis

2

First-in-Class Treatment for Unmet Medical Need

All Indications are potential Blockbusters

Potential Multiple Solid Tumors Treatment

Obtained ODD (US) on ALL

Estimated global market $6B

Most advanced candidate

$10M+ funding to date

NIH Blueprint Sponsored

Expected Drug Approval in 4 years

Seek Fast Track + Accelerated Approval

based on RBP4 biomarker predicting

clinical efficacy

Rare Pediatric Disease Designation (US) &

Orphan Drug Designation (US & EU)

Obtained RPD + ODD

Eligible for Priority Review Voucher upon

NDA

Worth $150-350M upon transfer

Eligible for PRV

Estimated global market for Stargardt +

AMD + NASH + Leukemia / Multiple Solid

Tumor

$1B + 20B + 20B + 6B Market

3

Pipeline

RBP4

Platform

Oncology

Programs

Dry AMD

Stargardt Disease

(FDA RPD, FDA ODD, EMA ODD)

Non Alcoholic Fatty Liver Disease

(NASH) / Type 2 Diabetes

Acute Leukemia (FDA ODD)

Multiple Solid Tumors

Glioblastoma /

Brain Metastasis

DISCOVERY PRE-CLINICAL PHASE I PHASE II / III MARKET

4

RBP4 PLATFORM

5

PLATFORM OVERVIEW

Anti-RBP4 PlatformTherapies for Aging

Metabolic Diseases

RBP4 protein transports

retinol (vitamin A) from the

liver to peripheral tissues. It is:

Highly Expressed

in the liver and adipose tissue

Easily Measured

via blood samples (ELISA)

Linked to Aging Metabolic

Diseases

Evidence linking elevated RBP4 to diabetes, liver

disease and macular degeneration

6

DISCOVERY

PHASE I

PHASE II/III

MARKET

PRE-CLINICAL

✓

Bring HOPE TO

INCURABLE BLINDESS

For Dry Age-Related Macular

Degeneration & Stargardt Disease

Anti-RBP4 Platform for Aging Metabolic Diseases

DISCOVERY

PHASE I

PHASE II/III

MARKET

PRE-CLINICAL✓

Block THE PATH TO

METABOLIC DISEASES

For Non-Alcoholic Fatty

Liver Disease & Type 2 Diabetes

7

MEET THE UNMET NEED

DISCOVERY

PHASE I

PHASE II/III

MARKET

PRE-CLINICAL

✓

Bring Hope To Incurable BlindnessFor Dry Age-Related Macular Degeneration & Stargardt Disease

10M

$20B170M

Blind victims suffer

from macular

degeneration in the US

Cases of AMD worldwide

with a global direct

healthcare cost of USD 255B

Estimated global market

1 in 10,000Stargardt Disease Juvenile onset

macular degeneration (rare

pediatric disease & orphan

disease)

MARKETKEY OPPORTUNITY

Zero ApprovedTreatments

RPD ODDfor Stargardt (US & EU)

Most Advanced Candidate

8

Reference: Globaldata, Lancet, Orphanet, STEM CELLS Translational Medicine

Symptoms of AMDPRODUCT DISEASE PROFILE

NormalCentral Vision

Blurry &Distorted

Central Vision

LostCentral Vision

Normal Macula

Early Dry AMDLipofuscin accumulation

Drusen formationand inflammation

Late Stage Geographic Atrophy

9

Pathogenesis of AMD & Stargardt DiseasePRODUCT DISEASE PROFILE

Normal Retina RPE Changes Rods Die, Cones Spared Cones Die

Vision Loss

10

MOA Overview: Visual Cycle

PHOTORECEPTORS

RETINAL PIGMENT

EPITHELIUM (RPE)

BLOODSTREAM

LBS-008 RBP4Inhibits RBP4 from delivering

retinal into RPE, reducing A2E

accumulation by 50%

Primary transporter of

retinal into RPE

Retinal isomers are required by normal visual function. They

are also precursors to the cytotoxic A2E

causing dry AMD and Stargardt.

RPE restores

once A2E level

reduces

A2E

Rhodopsin

RPE65 LRAT

11c-RDH

at-RDH

at-Ral11c-Ral

at-RE at-Rol11c-Rol

Down-Regulated

Retinal Isomers

Enzymes

Pigments

11

PRODUCT DISEASE PROFILE

Stargardt Disease: Juvenile Macular Degeneration

PHOTORECEPTORS

RETINAL PIGMENT

EPITHELIUM (RPE)

BLOODSTREAM

LBS-008 RBP4Inhibits RBP4 from delivering

retinal into RPE, reducing A2E

accumulation by 50%

Primary transporter

of retinal into RPE

Loss of

photoreceptors,

ERG abnormalities

A2E

(bisretinoid)

Rhodopsin

RPE65 LRAT

11c-RDH

at-Ral11c-Ral

at-RE at-Rol11c-Rol

at-RDH

ABCA4

COMPOUND TESTING IN THE ABCA4-/-RDH8-/- MICE

12

Reduces Bisretinoid Accumulation by 80%IN ABCA4-/-RDH8-/- MICE, COMPARED TO LBS-008-TREATED

1.75

26

6

56

48

3

p=0.003; unpaired t-test

Wild Type untreated control

DKOvehicle-treated control

DKOLBS-008-treated

Serum RBP4(ug/mL)

A2E Concentration(pmol per eye)

13

Degeneration in Abca4-/-Rdh8-/- MiceANIMAL STUDY DATA

0

10

20

30

40

50

60

70

ON

L th

ickn

ess

(μ

m)

inferior Distance from ONH superior

C57BL/6J DKO, untreated DKO, BPN14967-treated

Dry AMD or Stargardt’s is associated

with thinning of the outer nuclear layer

(ONL) and the loss of photoreceptor

cells, indicating macular

degeneration.

We quantified the ONL thickness and found ONL thickness

was significantly decreased in the diseased group

(abcd4/rdh8 knockout mice), as compared to the diseased

group treated with LBS-008, ONL were preserved, which

implies the treatment group has not loss photoreceptor cells. LBS-

008-

14

RBP4 Reduction Stops AMD ProgressionPRODUCT DISEASE PROFILE

“In the 300 mg fenretinide dose cohort…showed

a trend for slowing of lesion growth, particularly

among patients who had RBP and retinol levels

reduced by more than 50%.”

Pharmacotherapy of AMD Charpter 67, Mark S. Bluemenkranz (2015)

“Patients in the 300mg treatment group who completed the 2-year study

achieved reductions of RBP4 <2mg/dL correlated with further reductions of

lesion growth rate (a mean reduction of 0.33mm2 in yearly lesion growth).”

“Fenretinide treatment also reduced approx. 45% incidence of choroidal

neovascularization (Wet AMD)”

Investigation Of Oral Fenretinide For Treatment Of Geographic Atrophy in Age-Related Macular Degeneration

(Nathan L. Mata, PhD)

placebo

300 mg

Medium Lesion

Growth (50%)

RBP Reduction (%, from baseline)

Lesio

n In

cre

ase

(%, fr

om

baselin

e)

15

Robust Serum RBP4 ReductionMONKEY STUDY DATA

Seru

m R

BP

4(%

re

ductio

n)

Time (hours)

-80

-60

-40

-20

0

-100

0 12 24 36 48

90% Reduction48h after single dose

3X Better Than Targetfor Clinical Efficacy in Humans

16

Since LBS-008 reduces RBP4 in

the circulation and cleared from the

kidney, it can be easily measured

in blood and urine samples, and

thus the amount of retinol that gets

into the visual cycle can be

predicted and easily controlled and

managed.

NIH Endorsement

17

DISCOVERY

PHASE I

PHASE II/III

MARKET

✓

PRE-CLINICAL✓

Block The Path To Metabolic DiseasesFor Non-Alcoholic Fatty Liver Disease & Type 2 Diabetes

100M

$20B9M

Individuals with

NAFLD in the US alone

30% of general population

NASH cases in the US alone

3% of general population

Addressable total global market by

2025. Global market for type 2

diabetes estimated to reach $64B

by 2026

1.4BCases of NAFLD worldwide

MARKETKEY OPPORTUNITY

Zero ApprovedTreatmentsfor Non-Alcoholic Steatohepatitis (NASH)

18

Reference: NIH, Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease, Marketwatch, Globadata

RBP4 Contributes to Diabetes & Liver DiseasePRODUCT DISEASE PROFILE

51.7

62.8

Normal(n=86)

NAFLD(n=73)

23.5

61

70.6

NGT(n=19)

IGT(n=20)

T2D(n=20)

35.1

46.9

53

Control(n=30)

T2D(n=30)

T2D + NAFLD

(n=30)

**

**

***

RB

P4

(u

g/m

L)

P vs Normal P vs NGT

P vs Control

145 publications on RBP4 & Metabolic Syndrome

84 publications on RBP4 & Fatty Liver

“These findings suggest that

this newly defined adipokine

might be related to

pathogenesis of NAFLD.”

J A Seo et al. 2008

Clin Endocrinol. 68(4) 555-560

“Iinsulin resistance is the

strongest determinant of

elvated serum RBP4 levels

in IGT and T2D.”

Qin Yang et al. 2012

Endocrinology. 153(3): 1519-1527

“These findings suggest

that RBP4 might be related

to pathogenesis of

NAFLD.”

N A Ibrahim et al. 2016

Int J Adv Res Biol Sci 3(4): 71-79

19

RBP4 is Strongly Associated with CHD RiskPRODUCT DISEASE PROFILE

“We found that full-length RBP4 levels

were associated with a 3-fold increased

risk of incident CHD in women.”

Qi Sun et al. Circulation. 2013 May 14; 127(19): 1938–1947

Odds Ratio (95% CI) of CHD

at 8 Years Since Baseline

Quartiles of Plasma RBP4

Levels (full length, μg/mL)

1

0.7

1.58

3.56

Q1 Q2 Q3 Q4

“… Visceral fat … secretes hormones and a host

of other chemicals linked to diseases that

commonly afflict older adults. One such

substance is called RBP4 that was found in a 16-

year study of nurses to increase the risk of

developing coronary heart disease.”

New York Times, 2018 Jun 11

20

Childhood RBP4 levels are strong predictors of developing

Insulin Resistance and Metabolic Syndrome in AdultsPRODUCT DISEASE PROFILE

“high levels of childhood RBP4 at baseline were

associated with an adverse cardiovascular risk

profile at baseline and upon 10 year follow-up”

Li et al. Cardiovasc Diabetol (2018) 17:69

“The most striking, novel finding of this study is that RBP4 levels measured

in childhood were strong predictors of the subsequent development of

Metabolic Syndrome and each of its components (including insulin resistant,

hyperglycemia, hypertension and hyperlipidemia) 10 years later, and is

independent of obesity.”

• 10-year prospective study in 3445 children

• Participants with higher childhood RBP4 levels had adverse

cardiometabolic profiles at follow-up.

• RBP4 is a reliable indicator of innate Insulin Resistance and its ability to

predict the onset and persistence of Metabolic Syndrome after 10-year

follow-up

• After 10-year follow-up, baseline RBP4 (independent of BMI) predicted:

o Blood Pressures elevation (P = 0.015)

o Triglyceride elevation (P < 0.001)

o Hyperglycemia (P = 0.009)

o Insulin Resistance (P = 0.015)

o Metabolic Syndrome (P = 0.002)

21

RBP4 Also Found to Bind to Fatty AcidsPRODUCT DISEASE PROFILE

“We have shown that RBP4 is not specific for

retinol but it is also found in plasma, urine and

amniotic fluid bound to fatty acids.”

Massimiliano Perduca et al. Elsevier Data in Brief 18(2018). 1073-1081

RETINOL FATTY ACID

RBP4 side chains bound to RBP4 side chains bound to

22

MOA Overview: RBP4 in Liver Disease & DiabetesPRODUCT DISEASE PROFILE

APC activation+ inflammation

insulin resistance+ hypersecretion

NASHNon-Alcoholic Steatohepatitis

T2DType 2 Diabetes

LBS-009

FFA

TG

LIVER

PANCREAS

Enlarged Adipocytes

FAT TISSUE

RBP4

23

Up-Regulated

Down-Regulated

MOA Detail: RBP4 in DiabetesPRODUCT DISEASE PROFILE

FAT TISSUE

LIVER

SKELETAL MUSCLE

PANCREAS

β-Cell Compensation

Insulin

Resistance

PEPCK

T2D

Insulin Signal

RBP4

Glucose

Uptake

Enlarged

Adipocytes

MacrophageCD4 T Cell

Inflammatory

Cytokine

Secretion

TLR4

Glucose Uptake

Glucose Output

Insulin Output

24

Up-Regulated

Down-Regulated

MOA Detail: RBP4 in NAFLD / NASHPRODUCT DISEASE PROFILE

LIVER

AMPK Activation

NASH

NAFLDFFATG

Adiponectin

TLR4

Liver Inflammation

InsulinResistance

Up-Regulated

Down-Regulated

Glucose

Uptake

FAT TISSUE

Enlarged

Adipocytes

RBP4

MacrophageCD4 T Cell

Inflammatory

Cytokine

Secretion 25

Robust Serum RBP4 Reduction ANIMAL STUDY DATA

Seru

m R

BP

4 (

% r

ed

uctio

n)

Time (hours)

-100

-80

-60

-40

-20

0

0 8 12 24 48

85% Reduction12h after single dose

40% Reduction48h after single dose

26

Decreased Liver Lipid Deposition in HFD Animals

ANIMAL STUDY DATA

Liver Histology Score

0 2.9

Regular Diet +

VehicleHFD +

Vehicle

1.6

HFD +

LBS-009

regula

r die

t

HFD

HFD

+ C

om

pound

0

1

2

3

4

Liv

er h

isto

log

y s

co

re

****

****

***

Regular

Diet

HFD HFD +

LBS-009

Liv

er

His

tolo

gy S

co

re

27

ONCOLOGY

PROGRAMS

28

DISCOVERY

PHASE I

PHASE II/III

MARKET

PRE-CLINICAL✓

Natural non-ATP CDC7 Inhibitor

for treatment of Broad Variety of Cancers

KEY OPPORTUNITY

Novel Anti-Cancer

Target Therapy

29

$5B

$6B$55B

Expected 2026 market

size of AML & ALL

Expected 2023 market size

of pancreatic, lung, ovarian

cancers

Estimated global market

1.7 in 100kAcute lymphoblastic leukemia

(orphan disease)

MARKET

Reference: Globaldata, Marketwatch, NIH National Cancer Institute

ODDfor ALL (US)

Inhibits CDC7 in Cell Cycle Regulation

TARGETSS Phase Progression

1 2 3INHIBITSCDC7’s role in

DNA Replication

PREVENTSCell Division

LBS-007

30

HematopoieticCell Line

Primary PatientSample

Solid Tumor Cell Line

5 1000

EC50 (nanoM)

Lymphoma Breast CancerLung Cancer

Potently Inhibits Multiple Cancer Cell Lines &

Primary Patient Samples of Blood Cancers

31

LBS-007 – Effective Against Blood Cancers

DOSE-RESPONSIVE MANNER

32

Inhibits TKI-Resistant Acute

Lymphoblastic Leukemia

(ALL) growth in vivo using a

continuous infusion regimen

Reference: Unpublished data from Dr. Mark Frattini

D O R S A L V E N T R A L

LBS-007 – Also Effective Against

Solid Tumors in Animal Models

Control 0.3 1 3 mg/kg

DOSE-RESPONSIVE MANNER

33

Inhibits

Ovarian

Tumor

growth in vivo

Reference: Unpublished data from

Dr. Mark Frattini

This presentation is provided by Lin Bioscience, Inc. (“LBS”). The information contained within is not reviewed or reviewed by any accountant or any independent

third party. Users should read this material in conjunction with all other public financial and operational information filed to the competent authorities by LBS. While

we endeavor to provide accurate, complete and consistent information herein, LBS makes no guarantee or warranties as to the accuracy or correctness of all the

material contained. After this presentation is released to the public, we undertake no obligation to update any relevant data to reflect any change hereafter.

Users should also notice that this presentation may contain forward-looking statements. Statements that are not historical facts, including statements relating to the

implementation of strategic initiatives, future business development and economic performance are forward-looking statements. By their nature, forward-looking

statements involve uncertainties, risks, assumptions and other factors that could cause actual developments and results to differ materially from our statement in

this presentation. These factors include, but not limited to, regulatory developments, competitive conditions, technological developments, general economic

conditions and management changes.

The information, statements or opinions in this presentation do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of an

offer to buy any securities or financial instruments or any advice or recommendation respect to such securities or other financial instruments. LBS and all its

affiliates representatives, no matter for their negligence or any other reasons, should not be liable for any loss or damages arising from the use of or interpretation

by others of information contained within this presentation or any matter related to this document.

34

Blindness, Liver Fibrosis,

& Cancer

Hao-Yuan Chuang, CFO

hychuang@linbioscience.com

35